logo-loader
RNS
Surgical Innovations Group

Director/PDMR Dealings

RNS Number : 0207C
Surgical Innovations Group PLC
05 November 2026
 


5 November 2026

 

Surgical Innovations Group plc

(“Surgical Innovations”, “SI” or the "Company")

 

Director/PDMR Dealings

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery (“MIS”), was notified yesterday that, on 4 November 2026, David Marsh, Non-Executive Director, sold 5,000,000 ordinary shares of 1p each in Surgical Innovations (“Ordinary Shares”) at a price of 0.325 pence per share.

 

On the same day, Thalassa Holdings Ltd. purchased 5,000,000 Ordinary Shares of 1p each at a price of 0.325 pence per share. Under MAR, Thalassa Holdings Ltd. is a person closely associated to Duncan Soukup, who is a Non-Executive Director of the Company.

 

Following this transaction, David Marsh has a beneficial holding in the Company of 26,562,500 Ordinary Shares, representing approximately 2.85% of the issued share capital of the Company. And Thalassa Holdings Ltd. has a beneficial holding in the Company of 219,480,101 Ordinary Shares, representing approximately 23.53% of the issued share capital of the Company.

 

For further information please contact:

 

Surgical Innovations Group plc www sigroupplc com

Alex Warnock, CEO Tel: 0113 230 7597

David Anderson, CFO

 

Singer Capital Markets (Nominated Adviser & Broker) Tel: 020 7496 3000

Alex Bond / Peter Steel / Anastassiya Eley

 

Walbrook PR (Financial PR & Investor Relations) Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

David Marsh

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Surgical Innovations Group plc

b)

LEI

2138004GHGUH3HUZE156

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1p GB0004016704

b)

Nature of the transactions

Sale of Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s) per share

Volume(s)

 

0.325 pence

5,000,000

 

d)

Aggregated information

-             Aggregated volume

-             Price

 

5,000,000
0.325p

 

e)

Date of the transaction

4 November 2026

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Thalassa Holdings Ltd

2

Reason for the notification

a)

Position/status

Person closely associated with Duncan Soukup, Non‑Executive Director

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Surgical Innovations Group plc

b)

LEI

2138004GHGUH3HUZE156

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1p GB0004016704

b)

Nature of the transactions

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s) per share

Volume(s)

 

0.325 pence

5,000,000

 

d)

Aggregated information

-             Aggregated volume

-             Price

 

5,000,000
0.325p

 

e)

Date of the transaction

4 November 2026

f)

Place of the transaction

Outside of a trading venue

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company’s Resposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.

 

Further information

Further details of the Group's businesses and products are available on the following websites: www.sigroupplc.com

www.surginno.com www.elementalhealthcare.co.uk

 

To receive regular updates by email, please contact si@walbrookpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHAKPBQBBDDQDK
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read